Patricia Van Arnum

Patricia Van Arnum was executive editor of Pharmaceutical Technology.

Articles by Patricia Van Arnum

Pharmaceutical Technology Europe

The international Society of Chemical Manufacturers and Affiliates (SOCMA) has outlined its legislative priorities for 2010 for the second session of 111th Congress, plans for its national grassroots program — SOCMA Connect — and efforts to launch a voter-registration drive ahead of the November mid-term elections.

PTSM: Pharmaceutical Technology Sourcing and Management

Despite a challenging current economic environment, the five-year outlook for pharmaceutical outsourcing and ingredients supply is fairly healthy.

Growth in emerging markets and across the generic-drug sector shifts the global demand and supply of active pharmaceutical ingredients.

Pharmaceutical Technology Europe

Eli Lilly has outlined its growth strategy at its annual meeting with the investment community; chief among the company?s goals are plans to launch two new drugs per year beginning in 2013 and a strategy to increase its position in emerging markets.

PTSM: Pharmaceutical Technology Sourcing and Management

The custom manufacturer and fine-chemicals company adds further capabilities in high-potency and viral-product manufacturing and targets synergies in gene editing with its parent company, Sigma-Aldrich.

Pharmaceutical Technology Europe

The US Society for Chemical Manufacturers and Affiliates (SOCMA) has provided an update of its efforts regarding the recently passed US Chemical and Water Security Act of 2009 (HR 2868), which includes inherently safer technology (IST) requirements that SOCMA opposes.

ePT--the Electronic Newsletter of Pharmaceutical Technology

The Society for Chemical Manufacturers and Affiliates (SOCMA) provided an update as to its grassroots efforts regarding the recently passed Chemical and Water Security Act of 2009 (HR 2868).

Pharmaceutical Technology Europe

Following its $68-billion acquisition of Wyeth, Pfizer has unveiled detailed plans for its global R&D network, which includes consolidation of its R&D facilities.

ePT--the Electronic Newsletter of Pharmaceutical Technology

Following the its $68-billion acquisition of Wyeth (Madison, NJ), Pfizer (New York) Pfizer detailed plans for its global research and development (R&D) network, which includes consolidation of its R&D facilities.